Pfizer
Bordetella Bronchiseptica Bacterin, Cellular Antigen Extract
Contents: Bronchicine CAe is a nonadjuvanted antigenic extract prepared from the cells of Bordetella bronchiseptica. This product contains thimerosal (merthiolate) as a preservative.
Indications: Recommended for use as an aid in the control of Canine Infectious Tracheobronchitis (Kennel Cough) caused by the organism represented.
Directions: Shake well. Aseptically remove entire contents into the syringe. Push out any air trapped in the syringe. Administer 1 mL subcutaneously under loose skin (back of neck) to healthy dogs at least 8 weeks of age. Do not vaccinate into blood vessels. If blood enters the syringe, choose another injection site. For initial vaccination, a second dose is required 2-4 weeks later. This product should be administered by subcutaneous injection only. Annual revaccination with a single 1 mL dose is recommended.
Precaution(s): Store at 35°F-45°F (2°C-8°C). Do not freeze. Use entire contents when first opened.
Caution(s): Care should be taken to avoid microbial contamination of the product. In case of anaphylactoid reactions, epinephrine should be administered immediately. Transient local irritation at the site of injection, though rare, may occur subsequent to use of this product. For use in dogs only.
Discussion: The effect of persisting B. bronchiseptica maternal antibody on the immune response in puppies to this bacterin has not been determined. Puppies from bitches immune to the organism usually have low antibody titers that are dissipated by 4-6 weeks of age. Although kennel cough is considered a disease of complex etiology, it can be reproduced by challenge with B. bronchiseptica alone. A close association and/or confinement of dogs facilitates spread of the disease syndrome. Antibiotic therapy has been shown to be generally unsuccessful in reducing or eliminating B. bronchiseptica in dogs.
Presentation:10 dose (10 mL) vial.